Leerink cuts Immune Design to MP; PT to $3 from $7

Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY-ESO-1, and said it would focus development on G100, a TLR4 agonist. The stock closed at $2.79 on Oct. 11.

Read More
Melane LaBelle Sampson
Roth ups LeMaitre Vascular to buy; PT cut to $34

Roth Capital Partners upgraded LeMaitre Vascular (NASDAQ:LMAT) to “buy” from “neutral” but reduced its price target to $34 from $39 after the company reported in-line EPS for the third quarter of 2018, despite a $1.8-million revenue shortfall, and took down its 2018 guidance. The stock closed at $28.53 on Oct. 5.

Read More
Stephen Kilmer